Medipure Holdings Commences Trading on the Canadian Securities Exchange - Video News Alert on InvestmentPitch.com

November 13, 2014 11:01 AM EST | Source: InvestmentPitch Media

Vancouver, British Columbia--(Newsfile Corp. - November 13, 2014) - Medipure Holdings (CSE: MDH) is one of the latest new listings on the Canadian Securities Exchange. Medipure's goal is to conduct pioneering research into the development of cannabinoid-based medicines as prescription pharmaceuticals.

InvestmentPitch.com has produced a "video news alert" which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Medipure" in the search box.


If you cannot view the video above, please visit:
 http://www.investmentpitch.com/video/0_pl9qwrv1/Medipure-Holdings-CSE-MDH-New-Listing

The company intends to adopt a unique approach towards these pharmaceuticals, creating propriety cannabinoid derivatives that contain reduced tetrahydrocannabinol ("THC") content, are not delivered via inhalation, and are both designed and proven to effectively treat specific ailments.

In pursuit of this goal, Medipure has already begun to assemble an industry-leading team of medical professionals, led by Dr. John Maynard, the company's Chief Medical Officer and Chairman of Vancouver Coastal Health Authority's Medical Advisory Committee.

Based on more than two decades of trials, with a focus on strain identification and development through breeding and cross breeding programs, the Medipure Pharmaceutical technical team has developed a proprietary production process and facility design. It has also begun the development of its full service production and research facility in Maple Ridge, British Columbia, with the first phase of this development slated for completion in early 2015.

Medipure has formally applied to Health Canada for a Production and Research License, and expects to receive a decision regarding the status of its application during the first quarter of 2015. However, should the company not succeed in immediately securing a Producer's License, it will nonetheless be fully capable of conducting its research using product purchased from another Licensed Producer.

Medipure maintains in-house control over all aspects of the cannabinoid product development process - botanical research, extraction technology, formulation into drug delivery technologies, clinical trials and regulatory affairs. The company hopes to have its first derivative product prepared for market entry by the conclusion of 2015.

Boris Weiss, CEO, stated: "We're very pleased to have formally commenced trading upon the Canadian Securities Exchange. Access to the public markets will be critical in providing Medipure with the financial flexibility necessary to pursue our goal of revolutionizing cannabinoid-based medicines."

The company has 8.2 million shares outstanding. For more information, please visit the company's website www.medipurepharmaceuticals.com or contact Nathan Sellyn at 604-636-7051 or by email nsellyn@medipurepharma.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing short three minute videos based on significant news releases and research reports.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com

info